Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania RH Rhode Island South Carolina South Dakota Tennessee Texas Uncategorized Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 2603 blog entries.

Oklahoma

The legislature convened an interim hearing to examine the influence of PBMs on prescription drug pricing and patient access to local pharmacies. Chaired by Sen. Spencer Kern (R) and pharmacist Rep. T.J. Marti (R), the session highlighted significant concerns regarding below-cost pharmacy reimbursements, opaque pricing structures and patient steering practices. Expert testimony by Antonio Ciaccia, 46brooklyn Research, and others underscored systemic incentives that diminish transparency and raise costs. The Attorney General’s office and the Insurance Department reported recovering $32 million through enforcement actions, positioning Oklahoma as a national leader in PBM oversight. Legislators signaled intent to pursue comprehensive PBM reform legislation again in 2026, aimed at enhancing transparency, safeguarding independent pharmacies and ensuring equitable drug pricing.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2025-11-20T09:59:14-05:00November 20, 2025|Oklahoma|

South Carolina

Effective for dates of service on or after December 1, the Department of Health and Human Services (SCDHHS) is updating its billing policy for providers who purchase physician-administered drugs through the Health Resources and Services Administration’s (HRSA) 340B drug pricing program. The changes described in this bulletin only apply to services rendered to Healthy Connections Medicaid members in an outpatient setting who are enrolled in the fee-for-service Medicaid program. 

These policy updates will be published in the Physicians Services, Clinic Services, Hospital Services and Federally Qualified Health Center (FQHC) Services provider manual by December 1, 2025. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2025-11-20T09:58:43-05:00November 20, 2025|South Carolina|

Tennessee

The deadline to submit an attestation of low-volume status and proof of actual prescription volume to your contracted PBMs is December 1. Volume status is based on your pharmacy’s actual prescription volume from July 1, 2024, to June 30, 2025. For more information, please refer to the Department of Commerce and Insurance (TDCI) rules. The Tennessee Pharmacists Association’s PBM resource page also has some helpful information to assist you with this process.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2025-11-20T09:57:54-05:00November 20, 2025|Tennessee|

Massachusetts

The Board of Pharmacy shared the following updates. As a reminder, pharmacy practice documents, regulations and other resources are available on the website.  

Policy 2020-15: Scope of Practice  

Updates to this policy define "handling" of medications and that it requires an individual pharmacy license as well as defining the "prescription area" and who may access it.  

New Pharmacy Labeling Requirement 

Pharmacies must now label Schedule VI medications prescribed for reproductive or gender-affirming care with the name and address of the healthcare practice instead of the individual prescriber upon request from the prescriber.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2025-11-13T08:18:41-05:00November 13, 2025|Massachusetts|

New York

Effective November 6, Yeztugo® was covered as a pharmacy benefit by NYRx, the Medicaid Pharmacy Program, in addition to being covered by the Medicaid managed care medical benefit as a Practitioner-Administered Drug (PAD). To prevent pharmacy claim denial, it is important for the pharmacy to submit the claim for both oral and subcutaneous products on the same date of service.  

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2025-11-13T08:18:11-05:00November 13, 2025|New York|

Arizona

The Arizona Medicaid agency, the Arizona Health Care Cost Containment System and the Governor's Office invite you to attend this public webinar to learn more about Arizona's application for the Rural Health Transformation Program. This webinar will highlight the application submitted and will discuss the next steps regarding the program award and the funding of Arizona's programming. Click here to register and add to your calendar.  

Date: November 13  

Time: 11:30 am – 12:30 pm  

Location: Virtual Via Google Meet. Please register in advance. (Meeting ID and passcode will be provided upon registration)  

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2026-03-10T14:47:31-04:00November 7, 2025|Arizona, RH|

California

he Board of Pharmacy distributed its monthly News Roundup for November. This issue includes important information related to vaccines, albuterol and epinephrine standing orders for schools, the California Medication Error Reporting (CAMER), drug theft/drug loss online portal and PIC training webinar. 

Also in California, the November 2025 issue of the Board of Pharmacy's newsletter, The Script, is now published online. The November 2025 newsletter includes information on: 

  • New Laws 
  • Regulations 
  • Immunization Alert 
  • Importance of Patient Consent Forms 
  • CAMER 
  • Inspection Results 
  • Citations Issued 
  • Technology the Pharmacist's Role in Medication Safety 
  • Standing Orders for Schools Regarding Albuterol and Epinephrine 
  • Well-Being Index 

Also in California, the Board of Pharmacy sent the following reminder to licensees.  

Business and Professions Code (BPC) section 4113.1 establishes requirements for a community pharmacy to report medication errors known as CAMER to an entity approved by the Board. The statute requiring medication error reporting by community pharmacies can be viewed at BPC section 4113.1. The Board approved the Institute for Safe Medication Practices (ISMP), an ECRI Company, as the entity to receive and review medication error reports under BPC section 4113.1. Information regarding CAMER registration can be found at https://mederrors.ismp.org/.  

The Board reminds community pharmacy licensees that medication errors that occur on or after September 1, 2025, must be reported to the CAMER system consistent with legal requirements established.  

Also in California, the Department of Health Care Service posted the following on the Medi-Cal Rx Web Portal: 

 

Finally in California, pursuant to the announced pharmacy benefit policy changes effective January 1, 2026, the Department of Health Care Services (DHCS) mailed letters to Medi-Cal members to notify them of two upcoming changes:  

  • All Medi-Cal members received a letter concerning the exclusion of coverage for GLP-1 medications for weight-loss indications. 
  • Impacted Medi-Cal members received a letter concerning the need for prior authorization (PA) approval for select medications previously filled without a PA request. 

 Both letters provide members with information about the policy change and guidance concerning potential actions the member may take. 

Questions may be submitted to the Pharmacy Benefits Division at Medi-Cal.PharmacyBenefits@dhcs.ca.gov or to the Medi-Cal Rx Education and Outreach team at Medicalrxeducationoutreach@primetherapeutics.com 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2025-11-07T13:51:06-05:00November 7, 2025|California|
Go to Top